Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback